GMED’s free cash flow growth of 15% year-over-year is strengthening its balance sheet, improving resilience. Forecast models indicate a potential retest of 52-week highs if operational efficiencies persist. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). According to a different Grand View Research analysis, the US medical device manufacturing market is expected to reach a value of approximately $256.2 billion by 2024. Between 2025 and 2030, it is anticipated to expand at a compound annual growth rate of 5.9%. The growing frequency of traffic and sports accidents, the aging population, the geographic expansion of the major market participants, and the increased use of minimally invasive procedures in the sector are the main causes of this growth. Chart patterns show GMED forming a bullish rectangle, with traders anticipating a breakout upon earnings report release. The GMED stock price forecast suggests strong probability of hitting $67 in that technical scenario.